XORTX reports positive Phase 2 results in Type 2 diabetic nephropathy

XORTX Therapeutics (CSE:XRX; OTCQB:XRTXF), in conjunction with partner, Teijin Pharma, posted positive, statistically significant results with its TMX-049 drug candidate in a U.S. Phase 2 clinical trial in individuals with Type 2 diabetic nephropathy. 

The study was designed to test whether TMX-049 over a 12-week treatment period would decrease uric acid levels, and would provide a safe and effective therapeutic approach to decreasing albuminuria.

Study results showed that in patients with Type 2 diabetic nephropathy, TMX-049 could be safely administered to individuals in the tested dose range and was well tolerated; oral daily doses of TMX-049 could substantially and significantly decrease serum uric acid; and oral daily doses of TMX-049 decreased urinary albumin proteinuria to a substantial and statistically significant degree. 

“In the opinion of XORTX, TMX-049 is a leading next generation candidate xanthine oxidase inhibitor, with a desirable combination of strong clinical safety record and potent uric acid lowering capability,” Dr. Allen Davidoff, CEO, said in a statement. 

“The results of this study substantially increase the probability of advancing a first-in-class and best-in-class drug to slow and reverse progression of kidney disease in individuals with Type 2 diabetic nephropathy,” he added. 


Sign up to our weekly BioTuesdays newsletter.